C. Davis Todd's Insider Trades & SAST Disclosures
C. Davis Todd's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 93,476 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern C. Davis Todd.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 93,476 | 93,476 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 21,382 | 151,724 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 20,784 | 143,794 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 6,966 | 136,828 (0%) | 0% | 120 | 835,920 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 4,255 | 130,342 (0%) | 0% | 120 | 510,600 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 2,231 | 134,597 (0%) | 0% | 120 | 267,720 | Common Stock |
| Palvella Therapeutics Inc. | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 24,700 | 24,700 | - | - | Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 97.39 per share. | 08 Aug 2024 | 2,500 | 123,010 (0%) | 0% | 97.4 | 243,481 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Other type of transaction at price $ 60.71 per share. | 28 Jun 2024 | 350 | 120,510 (0%) | 0% | 60.7 | 21,247 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.20 per share. | 25 Mar 2024 | 7,448 | 111,593 (0%) | 0% | 46.2 | 344,098 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 7,448 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.19 per share. | 25 Mar 2024 | 3,556 | 120,160 (0%) | 0% | 66.2 | 235,372 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 3,556 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.24 per share. | 25 Mar 2024 | 2,855 | 114,448 (0%) | 0% | 67.2 | 191,970 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 2,855 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.51 per share. | 25 Mar 2024 | 2,156 | 116,604 (0%) | 0% | 68.5 | 147,708 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 2,156 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | C. Davis Todd | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 131,723 | 131,723 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | C. Davis Todd | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 32,436 | 104,145 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Davis Todd C. | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.65 per share. | 15 Feb 2024 | 1,381 | 71,709 (0%) | 0% | 74.7 | 103,092 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.76 per share. | 09 Jun 2023 | 420 | 69,090 (0%) | 0% | 73.8 | 30,979 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 46,178 | 46,178 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 17,005 | 68,791 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 2,081 | 2,081 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 132,000 | 132,000 | - | - | Employee Stock Option (right to buy) | |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2022 | 718 | 30,176 (0%) | 0% | 0 | common shares | |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.05 per share. | 14 Oct 2022 | 418 | 29,458 (0%) | 0% | 47.1 | 19,667 | common shares |
| Vaxart Inc | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2022 | 44,224 | 44,224 | - | - | Stock Option (right to buy) | |
| Vaxart Inc | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2022 | 7,375 | 125,905 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 51,786 (0%) | 0% | 0 | Common Stock | |
| Vaxart Inc | Todd C. Davis | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Dec 2021 | 1,470 | 118,530 (0%) | 0% | 0 | Common Stock | |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 5,824 | 32,162 (0%) | 0% | 0 | common shares | |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.99 per share. | 01 Oct 2021 | 3,110 | 29,052 (0%) | 0% | 41.0 | 127,479 | common shares |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 824 | 29,876 (0%) | 0% | 0 | common shares | |
| Vaxart Inc | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 15,097 | 15,097 | - | - | Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 50,782 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Sale of securities on an exchange or to another person at price $ 213.14 per share. | 10 Feb 2021 | 5,083 | 47,678 (0%) | 0% | 213.1 | 1,083,410 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 195.91 per share. | 10 Feb 2021 | 2,474 | 50,152 (0%) | 0% | 195.9 | 484,681 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 2,474 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 113.50 per share. | 27 Jan 2021 | 2,456 | 52,761 (0%) | 0% | 113.5 | 278,756 | Common Stock |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 2,456 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.04 per share. | 25 Jan 2021 | 369 | 27,793 (0%) | 0% | 25.0 | 9,240 | common shares |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2020 | 7,476 | 29,517 (0%) | 0% | 0 | common shares | |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.25 per share. | 02 Oct 2020 | 3,312 | 26,205 (0%) | 0% | 17.3 | 57,132 | common shares |
| Franklin Covey Co. | Clifton Todd Davis | VP People Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2020 | 1,957 | 28,162 (0%) | 0% | 0 | common shares | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 2,468 | 2,468 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 831 | 50,305 (0%) | 0% | 0 | Common Stock | |
| Vaxart Inc | Todd C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 65,700 | 65,700 | - | - | Stock Option (right to buy) | |
| Vaxart Inc | Todd C. Davis | Director | Sale of securities on an exchange or to another person at price $ 3.28 per share. | 28 Apr 2020 | 60,000 | 120,000 (0%) | 0% | 3.3 | 196,500 | Common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges